by Jessica Nye, PhD
Patients with platinum-resistant epithelial ovarian cancer may have better overall survival (OS) if they enroll on a clinical trial than if they receive standard care, according to study results presented at the 2023 SGO Annual Meeting on Women’s Cancer.
“Our data suggest that clinical trial participation should be prioritized in the platinum- resistant patient population, when possible,” said study presenter Molly Morton, MD, of Cleveland Clinic Foundation and The Ohio State University.
Dr Morton and colleagues evaluated 305 patients with platinum-resistant epithelial ovarian cancer who were treated at The Cleveland Clinic during 2009-2017. Most patients (n=259) received standard care, but 46 were enrolled on clinical trials.
The trial participants were enrolled in 1 of 21 trials, and the median time on trial was 3.9 months.
The mean age was 61.2 years in the clinical trial group and 63.3 years in the standard care group. The groups had similar rates of hypertension (41.3% and 42.9%, respectively), diabetes (15.2% and 10.8%), coronary artery disease (8.7% and 15.4%), and chronic kidney disease (2.2% and 5.0%).
Similar proportions of patients in the clinical trial and standard care groups had stage III ovarian cancer (87.0% and 81.5%, respectively), had serous histology (95.7% and 90.7%), received intraperitoneal chemotherapy (13.3% and 14.7%), received bevacizumab (22.2% and 32.1%), received PARP inhibitors (21.7% and 15.1%), and underwent secondary cytoreductive surgery (8.7% and 10%).
However, the trial participants were exposed to more total lines of therapy. The median number of treatment lines was 5 in the trial group and 4 in the standard care group (P <.001).
There was no significant difference between the groups in time to platinum resistance. However, OS from the time of platinum resistance was superior in the clinical trial group.
The median OS from platinum resistance was 13.8 months in the clinical trial group and 10.5 months in the standard care group (hazard ratio, 1.46; 95% CI, 1.04-2.05; P =.028). The 3-year OS rate was 19.6% and 8.6%, respectively.
Disclosures: Dr Morton reported having no conflicts of interest.
Morton M, Yao M, Chalif J, et al. Clinical trial participation is associated with improved overall survival in patients with platinum resistant epithelial ovarian cancer. SGO 2023. March 25-28, 2023.
This article was published by Cancer Therapy Advisor.